Explore News By Topic


Genetic Counseling Center Dedicated To Advanced Prostate Cancer Opens In Seattle

Prostate cancer is one of the most heritable forms of cancer. Hereditary mutations in “DNA repair” genes – BRCA1, BRCA2, and others – which are best known for their association with breast and ovarian cancer predisposition, are now known to be associated with advanced prostate cancer. In fact, ~12% of.


The Prostate Cancer Foundation’s 2016 Coffey-Holden Prostate Cancer Academy Meeting Accelerates Advances In The Understanding And Treatment Of Metastatic Prostate Cancer

The Prostate Cancer Foundation (PCF) has a legacy of not only funding the most impactful research in prostate cancer, but also creating new infrastructures, global knowledge networks, and research initiatives that support and accelerate prostate cancer research towards better treatment for advanced prostate cancer patients. For the past four years,.


Metastatic Prostate Cancer Cases Skyrocket Increase May Be Due To More Lax Screening Or More Aggressive Disease

Highest increase among men ages 55 to 69, who could benefit the most from screening and early treatment. Disease is more advanced when finally diagnosed. "Screening saves lives," urologists stress. "If I were a patient, I would want to be vigilant." Chicago -- The number of new cases of metastatic.


New study finds one in nine men with metastatic prostate cancer carry inherited mutations in DNA repair genes with important implications for treatment and for cancer risk in family members

https://www.youtube.com/embed/8pjv5M7G58U Cancer, the uncontrolled growth of cells, is caused by the acquisition of genetic mutations that allow cells to evade the normal biological laws governing when and where they can grow in the body. Mechanisms that maintain the accuracy of our genomes are critical for preventing cells from collecting mutations.



Mutations in 16 different DNA damage repair (DDR) genes have been identified as drivers of metastatic prostate cancer and other tumors, but are rare in the general population Approximately 12% of men with metastatic prostate cancer harbor inherited (germline) DDR mutations that likely caused their disease, even if they have.



  SANTA MONICA, CA June 23, 2016 – The Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) Awards to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the Class of 2016 were selected from a pool of 128 applicants from 77.


New Clinical Trial Endpoint May Speed The Development Of New Therapies For Patients With Localized Prostate Cancer

At the 2016 American Society of Clinical Oncology (ASCO) Annual Conference, Dr. Christopher Sweeney presented results from ICECaP (Intermediate Clinical Endpoints in Cancer of the Prostate), a Prostate Cancer Foundation (PCF)-supported initiative, that will halve the time required to assess new therapies for aggressive prostate cancer. "We need to move.


Obesity And A High-fat Diet Promote Prostate Cancer Progression By Amplifying The Activity Of Cancer Genes

At the 2016 Annual American Association for Cancer Research (AACR) Conference, Giorgia Zadra, PhD, of the Harvard: Dana-Farber Cancer Institute and Brigham and Women's Hospital, presented results from a study that helped to clarify the relationship between obesity and prostate cancer. The skinny? Fat increases the activity of a critical.


Trailblazing Study Optimizes Anti-androgen Therapy For Advanced Prostate Cancer Patients

A recent study funded by the Prostate Cancer Foundation (PCF) reports a new strategy for "fine-tuning" how the body processes abiraterone to optimize therapy for men with metastatic, treatment-resistant prostate cancer (mCRPC). These exciting results were published in the May 26 issue ofNature. "Overall, our findings shed light into new.


Inherited Defects In Breast And Ovarian Cancer Genes Predispose To Prostate Cancer With Worse Outcomes

At the 2016 American Association for Cancer Research (AACR) Annual Meeting, Dr. Joaquin Mateo, a medical oncologist at the Institute for Cancer Research, UK, presented results from a new study which assessed hormone therapy-resistant prostate cancer patients for the prevalence of hereditary alterations in DNA repair genes. An estimated 50-60%.